GPR132 and breast cancer: Remarkably, the positive association of Gpr132 with inflammation and breast cancer in human (Figure 4B–F), the repression of Gpr132 expression by rosiglitazone in human macrophage (Figure 4A) and the anti-tumor effects of pharmacological Gpr132 inhibition (Figure 5O–P) highlight the exciting potential of Gpr132 blockade as a new therapeutic.